This action might not be possible to undo. Are you sure you want to continue?
Wednesday 4 April, 2012
A spokesperson for ANSTO said: “The Australian Nuclear Science and Technology Organisation (ANSTO) has received a copy of a report following the Australian Government Competitive Neutrality Complaints Office (AGCNCO) investigation into commercial practices at PETNET Australia Pty Limited (PETNET). “PETNET manufactures and sells the most common PET radiopharmaceutical, fluoro-deoxy glucose (FDG), which is used in medical scans for diagnosis of tumours and a range of brain and heart diseases. “In its report, AGCNCO has made four findings. In three cases it found no breach of the Government’s Competitive Neutrality Policy. In a fourth case it found an ex ante breach of the policy, and has made two recommendations as a result. “ANSTO will now carefully consider the report, its recommendations, and the need to ensure continued supply of radiopharmaceuticals to Australian patients. “That said, ANSTO notes that Royal Prince Alfred Hospital produces and sells FDG at significantly lower prices than both PETNET and Cyclopharm. “In addition, PETNET is the only supplier of FDG whose quality is certified by the Therapeutic Goods Administration (AUST-R number 78935).” Media contact: 02 9717 9208 or 0467 818 132